- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech High Growth Potential Companies
Australian Pharmaceuticals & Biotech High Growth Potential Companies
Results
15
Companies with a Future performance score of at least 3, ordered by Future performance score.
15 companies
Acrux
Market Cap: AU$6.1m
Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
ACR
AU$0.015
7D
7.1%
1Y
-76.9%
Mesoblast
Market Cap: AU$3.1b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.18
7D
-8.4%
1Y
111.7%
Clinuvel Pharmaceuticals
Market Cap: AU$628.0m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$10.65
7D
-17.6%
1Y
-32.1%
Immutep
Market Cap: AU$359.6m
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.23
7D
-7.8%
1Y
-42.0%
Cynata Therapeutics
Market Cap: AU$45.2m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.21
7D
10.5%
1Y
7.7%
Botanix Pharmaceuticals
Market Cap: AU$294.2m
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.
BOT
AU$0.14
7D
-3.3%
1Y
-63.7%
Genetic Signatures
Market Cap: AU$68.1m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.27
7D
-8.5%
1Y
-64.0%
Telix Pharmaceuticals
Market Cap: AU$5.1b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$14.60
7D
-20.3%
1Y
-21.5%
Medical Developments International
Market Cap: AU$65.3m
Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.
MVP
AU$0.58
7D
-5.6%
1Y
44.4%
Clarity Pharmaceuticals
Market Cap: AU$1.2b
A clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.
CU6
AU$2.98
7D
-12.1%
1Y
-58.8%
Aroa Biosurgery
Market Cap: AU$224.3m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.65
7D
0%
1Y
19.3%
EZZ Life Science Holdings
Market Cap: AU$116.0m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.
EZZ
AU$2.35
7D
-9.3%
1Y
-11.7%
Trajan Group Holdings
Market Cap: AU$142.5m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.92
7D
-1.1%
1Y
-20.0%
PYC Therapeutics
Market Cap: AU$752.4m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.28
7D
-1.5%
1Y
-8.6%
Neuren Pharmaceuticals
Market Cap: AU$2.5b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$19.01
7D
10.7%
1Y
21.9%